JP2018505658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505658A5 JP2018505658A5 JP2017530266A JP2017530266A JP2018505658A5 JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5 JP 2017530266 A JP2017530266 A JP 2017530266A JP 2017530266 A JP2017530266 A JP 2017530266A JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- tumor
- rna
- score
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 41
- 206010028980 Neoplasm Diseases 0.000 claims 37
- 230000004547 gene signature Effects 0.000 claims 29
- 239000000523 sample Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 18
- 230000014509 gene expression Effects 0.000 claims 17
- 230000004044 response Effects 0.000 claims 15
- 229940124060 PD-1 antagonist Drugs 0.000 claims 10
- 230000006023 anti-tumor response Effects 0.000 claims 10
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 230000002596 correlated effect Effects 0.000 claims 4
- 230000002601 intratumoral effect Effects 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000003733 ovarian melanoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089538P | 2014-12-09 | 2014-12-09 | |
| US62/089,538 | 2014-12-09 | ||
| US201562160284P | 2015-05-12 | 2015-05-12 | |
| US62/160,284 | 2015-05-12 | ||
| PCT/US2015/064445 WO2016094377A1 (en) | 2014-12-09 | 2015-12-08 | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505658A JP2018505658A (ja) | 2018-03-01 |
| JP2018505658A5 true JP2018505658A5 (enExample) | 2018-12-27 |
Family
ID=56108044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530266A Pending JP2018505658A (ja) | 2014-12-09 | 2015-12-08 | Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11377693B2 (enExample) |
| EP (1) | EP3230498B1 (enExample) |
| JP (1) | JP2018505658A (enExample) |
| KR (1) | KR20170086661A (enExample) |
| CN (1) | CN107109700A (enExample) |
| AU (2) | AU2015360736A1 (enExample) |
| BR (1) | BR112017012222A2 (enExample) |
| CA (1) | CA2968406A1 (enExample) |
| MX (1) | MX2017007535A (enExample) |
| RU (1) | RU2017123117A (enExample) |
| WO (1) | WO2016094377A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365479B (zh) | 2005-12-02 | 2013-06-26 | 纽约大学西奈山医学院 | 呈现非天然表面蛋白的嵌合病毒及其应用 |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| EP3441084A1 (en) | 2014-02-27 | 2019-02-13 | Viralytics Limited | Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| EP3283882B2 (en) | 2015-04-17 | 2024-10-16 | Merck Sharp & Dohme LLC | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10438699B2 (en) * | 2016-05-10 | 2019-10-08 | Macau University Of Science And Technology | Method and system for determining an association of biological features with a medical condition |
| WO2018067937A1 (en) * | 2016-10-07 | 2018-04-12 | Omniseq, Inc. | Methods and systems for determining personalized therapies |
| US20190376146A1 (en) * | 2016-11-24 | 2019-12-12 | Daiichi Sankyo Company, Limited | Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3095331A1 (en) * | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| WO2019213478A1 (en) | 2018-05-04 | 2019-11-07 | Nanostring Technologies, Inc. | Gene expression assay for measurement of dna mismatch repair deficiency |
| US20210123919A1 (en) | 2018-05-14 | 2021-04-29 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| WO2019226514A2 (en) * | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| WO2020005068A2 (en) * | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| CN113260633A (zh) * | 2018-12-05 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 用于癌症免疫疗法的诊断方法和组合物 |
| WO2020243568A1 (en) * | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| EP4010022A4 (en) * | 2019-08-09 | 2024-01-17 | The Regents of University of California | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF BLADDER CANCER |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| EP4055054A4 (en) * | 2019-11-04 | 2024-06-05 | Merck Sharp & Dohme LLC | ANGIOGENESIS- AND MDSC-GENE EXPRESSION-BASED TUMOR MARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS |
| WO2021110927A1 (en) * | 2019-12-04 | 2021-06-10 | Servicio Andaluz De Salud | Method to predict the response to cancer treatment with anti-pd1 immunotherapy |
| CN111088360A (zh) * | 2020-01-17 | 2020-05-01 | 暨南大学 | Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用 |
| CN115515585A (zh) | 2020-03-10 | 2022-12-23 | X4 制药有限公司 | 用于治疗中性粒细胞减少症的方法 |
| WO2022074648A1 (en) * | 2020-10-05 | 2022-04-14 | 4C Biomed Limited | Marker for response to pd-1/pd-l1 immunotherapy |
| WO2022135402A1 (zh) * | 2020-12-24 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Pd-l1和/或mhc-2生物标记物在预测肺癌患者治疗疗效中的用途 |
| AU2022315526A1 (en) * | 2021-07-22 | 2024-02-29 | Asylia Diagnostics Bv | Biomarkers for therapy response after immunotherapy |
| AU2022424122A1 (en) | 2022-01-03 | 2024-07-25 | Checkmate Pharmaceuticals, Inc. | Transcriptional biomarkers for response to innate immune activators |
| WO2023244632A1 (en) * | 2022-06-17 | 2023-12-21 | Merck Sharp & Dohme Llc | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024112609A1 (en) * | 2022-11-21 | 2024-05-30 | Merck Sharp & Dohme Llc | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| WO2024225488A1 (ja) * | 2023-04-27 | 2024-10-31 | 株式会社リプロセル | 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法 |
| WO2025034883A1 (en) | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| WO2025106905A1 (en) | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination therapies with a kras modulator and an immunomodulator inhibitor |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| DE3924454A1 (de) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips) |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| EP0636186B1 (en) | 1992-04-03 | 1998-11-25 | The Perkin-Elmer Corporation | Probe composition and method |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| DE4311230C2 (de) | 1993-04-02 | 1996-12-19 | Mannesmann Ag | Nicht-spurgebundenes Fahrzeug mit Elektromotor |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| DE69735112T2 (de) | 1996-11-06 | 2006-09-07 | Sequenom, Inc., San Diego | Verfahren zur Analyse und Vorrichtung |
| DE69706187T2 (de) | 1996-11-06 | 2002-04-11 | Sequenom, Inc. | Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern |
| US6077674A (en) | 1999-10-27 | 2000-06-20 | Agilent Technologies Inc. | Method of producing oligonucleotide arrays with features of high purity |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| AU2005243410B2 (en) | 2004-05-14 | 2010-04-22 | Rosetta Genomics Ltd. | Micronas and uses thereof |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| JP2011502513A (ja) * | 2007-11-09 | 2011-01-27 | ジェネンテック， インコーポレイテッド | 癌患者における診断用途のための方法および組成物 |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| TW202114735A (zh) | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| MX2014006241A (es) * | 2011-11-23 | 2015-03-03 | Amgen Inc | Metodos de tratamiento usando un anticuerpo contra interferon gamma. |
| US11242564B2 (en) | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| WO2014015011A1 (en) * | 2012-07-19 | 2014-01-23 | Tensorcom, Inc. | Method and apparatus for the alignment of a 60 ghz endfire antenna |
| WO2014022826A2 (en) * | 2012-08-03 | 2014-02-06 | Icahn School Of Medicine At Mount Sinai | Biomarker associated with risk of melanoma reoccurrence |
| KR20220053691A (ko) * | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| WO2014194293A1 (en) * | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| US20160312297A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3084003A4 (en) | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3084001A4 (en) | 2013-12-17 | 2017-07-12 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3283882B2 (en) | 2015-04-17 | 2024-10-16 | Merck Sharp & Dohme LLC | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
-
2015
- 2015-12-08 CN CN201580072918.XA patent/CN107109700A/zh active Pending
- 2015-12-08 US US15/533,769 patent/US11377693B2/en active Active
- 2015-12-08 RU RU2017123117A patent/RU2017123117A/ru not_active Application Discontinuation
- 2015-12-08 CA CA2968406A patent/CA2968406A1/en not_active Abandoned
- 2015-12-08 WO PCT/US2015/064445 patent/WO2016094377A1/en not_active Ceased
- 2015-12-08 JP JP2017530266A patent/JP2018505658A/ja active Pending
- 2015-12-08 EP EP15868101.5A patent/EP3230498B1/en active Active
- 2015-12-08 KR KR1020177018558A patent/KR20170086661A/ko not_active Withdrawn
- 2015-12-08 AU AU2015360736A patent/AU2015360736A1/en not_active Abandoned
- 2015-12-08 MX MX2017007535A patent/MX2017007535A/es unknown
- 2015-12-08 BR BR112017012222A patent/BR112017012222A2/pt not_active Application Discontinuation
-
2020
- 2020-07-08 AU AU2020204557A patent/AU2020204557A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505658A5 (enExample) | ||
| Mohan et al. | Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC | |
| RU2017123117A (ru) | Система и способы получения биомаркеров генных сигнатур ответа на антагонисты pd-1 | |
| Wang et al. | Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing | |
| Wong et al. | Poor survival with wild-type TP53 ovarian cancer? | |
| Ramaker et al. | RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature | |
| JP2017508970A5 (enExample) | ||
| Popovici et al. | Selecting control genes for RT-QPCR using public microarray data | |
| CN113444804B (zh) | 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用 | |
| JP2017529859A5 (enExample) | ||
| CN112908470A (zh) | 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用 | |
| CN107974506A (zh) | 一种用于急性髓系白血病药物指示的方法及装置 | |
| CN106148529A (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| JP2016515800A5 (enExample) | ||
| JP2016073287A (ja) | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット | |
| CN117625793B (zh) | 一种卵巢癌生物标志物的筛选方法及其应用 | |
| Gu et al. | Inflammation-related LncRNAs signature for prognosis and immune response evaluation in uterine corpus endometrial carcinoma | |
| Kaur et al. | Comprehensive identification of pleiotropic loci for body fat distribution using the NHGRI‐EBI Catalog of published genome‐wide association studies | |
| CN109880905B (zh) | 一组用于三阴性乳腺癌免疫组化分型的基因及其应用 | |
| Laborde et al. | Transcriptional profiling by sequencing of oropharyngeal cancer | |
| Shen et al. | Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA | |
| CN107653312B (zh) | 与血脂水平和冠心病相关的rs7901016检测系统及相关应用 | |
| Munkácsy et al. | Gene expression-based prognostic and predictive tools in breast cancer | |
| Greenberg et al. | Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor | |
| CN118711662A (zh) | 一种乳腺癌患者新辅助化疗敏感性的预测装置 |